Maxygen will receive a $30 million payment from Bayer HealthCare for Bayer’s continued clinical development of a recombinant factor VIIa product candidate for the treatment of hemophilia.   Maxygen sold the product candidate to Bayer, along with its other hematology assets, in July 2008 for $90 million in cash. The additional $30 million payment was based on further development of the factor VIIa product candidate, as well as the satisfaction of certain patent-related conditions. Maxygen is not ...